[20180119]LSB10064_不可能优先购买是不可能的吗?联邦毒品法和州侵权索赔的优先权.pdf

上传人:任我行 文档编号:26949 上传时间:2022-06-24 发布时间:2019-04-30 格式:PDF 页数:4 大小:744.17KB
下载 相关 举报
[20180119]LSB10064_不可能优先购买是不可能的吗?联邦毒品法和州侵权索赔的优先权.pdf_第1页
第1页 / 共4页
[20180119]LSB10064_不可能优先购买是不可能的吗?联邦毒品法和州侵权索赔的优先权.pdf_第2页
第2页 / 共4页
[20180119]LSB10064_不可能优先购买是不可能的吗?联邦毒品法和州侵权索赔的优先权.pdf_第3页
第3页 / 共4页
[20180119]LSB10064_不可能优先购买是不可能的吗?联邦毒品法和州侵权索赔的优先权.pdf_第4页
第4页 / 共4页
亲,该文档总共4页,全部预览完了,如果喜欢就下载吧!
资源描述

1、CRS INSIGHT Prepared for Members and Committees of Congress Legal SidebarLegal Sidebari i Is Impossibility Preemption Impossible? Federal Drug Law and Preemption of State Tort Claims January 19, 2018 Federal preemption, which is grounded in the Constitutions Supremacy Clause, has long been one of th

2、e most important and heavily debated defenses for the manufacturers of drugs and medical devices against state tort lawsuits. In this vein, the question of when “impossibility preemption” a form of implied preemption that exists where it is impossible for a private party to comply with both state an

3、d federal law should shield drug manufacturers from liability in state-law failure-to-warn claims has long been the subject of dispute, resulting in conflicting opinions from the Supreme and lower courts. The crux of the tension surrounding preemption in this context is a policy debate while consume

4、r advocates argue that state tort liability is key to ensuring patient safety, drug manufacturers urge that such laws may limit patient access to drugs by leaving innovators vulnerable to costly litigation and undermining FDAs authority. Against this backdrop, the Supreme Court is considering whethe

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告